


EuroSciCon

Biosimilars
2023

4th International Conference on

Biosimilars and Biologics

October 02-03, 2023 | London, UK

Theme: New Horizons in Biosimilars and Biologics

Invitation

We are glad to announce the 4th International Conference on Biologics, Biosimilars and Biomarkers to be held in London, UK from October 02-03, 2023 organized by EuroSciCon ltd, UK in collaboration with generous support and cooperation from enthusiastic academicians and editorial Board Members.

Leading Biosimilars Experts, Scientists, Societies, Researchers, Directors of Association, professors, Students, and other young professionals gather in London, UK to speak and explore at Biosimilars-2023. , we have developed a program with your interests in mind. We have not only increased the number of opportunities for you to network with colleagues from across the world but also introduced more focused sessions that will feature cutting edge presentations, special panel discussions, and livelier interaction with industry leaders and experts.

Life is about learning every day. Make it count in your professional life. Attend Biosimilars-2023 Conference Conference to network with your peers, exchange expertise and experiences, and arm yourself with the latest information to take your department to the next level.

We look forward to personally welcoming you to London, UK



EuroSciCon

A Transformational Learning Experience

1. Curated to address the concerns of today's scientific world
2. Be inspired by some of the world's most renowned figures
3. Stimulate new ways of thinking and provoke action.
4. Relish inspiring interaction between peers, leaving you better prepared to face technical and research oriented challenges.



Why with us?

We at EuroSciCon strive to create transforming experiences, propelling researchers and organizations to interact and come up with actionable ideas thus enhancing the quality of research and development.

And here's why you associate with us

Our International Open Access Journals:

We embrace around 700+ Leading-edge Peer Reviewed Open Access Journals and a 21 Day Rapid Review Process with a whopping 50000+ Editorial Board Team, 35000+ Reviewers team and 1000+ Scientific Associations Collaborations.

Read by over 30 Million Patrons and 100000+ Facebook Likes comprehending the High online presence, our Open Access Journals serve the best blend of content and global exposure.

Our International Scientific Conferences:

With over 3000 Conferences happening across the globe in the streams of Medical, Pharma, Engineering, Science, Technology and Business our events are accredited with CME/CPD.

Moreover you get to meet the industry's high priests who come from all over the orb. You learn from the companies defined by their progressive ethos and dynamic strategies and also through the highly interactive sessions and panel discussions.

B2B Meetings with enriching interaction help building better businesses, people and world.

Other salient features comprehend:

Publishing of the accepted abstracts in our inordinately indexed journals

Each of which will be labelled with a Digital Object Identification Number (DOI) provided by Cross Ref Distinct abstract and Speaker page creation, which profusely aid in citing the research and researcher in the top search engines.

Career Guidance Workshops for students and early career researchers

Opportunity to publish full Manu Scripts in our Open Access Journals



With over 25000+ Practitioners and Educators accessing the website, Biosimilars-2023 is the most lucrative platform for Professors, Researchers, Academicians and Industry professionals pursuing their work in the field. In addition to immense networking opportunities, global prominence of the research and the researcher is what we bestow our Speakers and Committee Members fuelling better outreach of the work and profile.

Biosimilars-2023 Salient Features:

Biosimilar medicine or follow-on biologics are products designed to act in a similar way to the originator or reference product that has been previously approved for a particular disease. Biosimilars are not the same as generics, see Table 1, which have simpler chemical structures and are considered to be identical to their reference medicines. Biosimilars have been proven, through rigorous clinical trials, to have a high similarity to the reference biological in terms of quality, efficacy and safety.

How's EuroSciCon different?

Exercises your creative instincts with the live knowledge experience
It organizes 3000+ Conferences across the globe connecting different sciences in 30+ countries
Over 25 Million+ Visitors and 20000+ Unique Visitors per conference
World's leading industries and companies attend
Career guidance for early career researchers and students
Provides insights you need to take your research to the next level
A huge conclave of high tech and science priests

Who'd be attending?

Leading World Industrialists Biosimilars Professionals, Professors, Research fellows, Leading Universities, Students, Directors of association and societies. Biosimilars-2023 conference conference brings together individuals who have an interest in different fields of plays host for the Multinational organizations, entrepreneurs across the globe, the researchers and academicians. Prominently Biosimilars, and Delegates from Medical Laboratories and Drug Designing Companies, Directors/Co-Directors of Research based companies across Europe and US who are investing in Immunology and Infectious Diseases and others who stay plunged in learning and practice of the science of technology. It is a forum to explore issues of mutual concern as well as exchange knowledge, share evidence, ideas, and generate solutions.

About hosting organization

EuroSciCon is one among Europe's largest and most significant scientific place which serves as a crossroad for the academicians and industry experts to build networks. With over 16 years of Life Science Communication it focuses on to Spearheading the Transformation of Medical Research into Knowledge through Scientific Gatherings and Networking. Supporting the Rare Care UK organization, EuroSciCon is a corporate member of Royal Society of Biology, Institute of Biomedical Science (IBMS) and British Society for Immunology. Our approach has always been unique, and that difference has propelled our growth towards Scientific Serendipity.

Scientific Sessions:

- Current Challenges In Developing Biosimilars
- Biosimilars In Therapeutics
- Clinical Trials Of Biosimilars
- Biosimilars In Oncology
- Monoclonal Antibody Biosimilars
- Drug Development And Delivery
- Biopharmaceuticals
- Biosimilars Pipeline
- Biosimilar Switch
- Biological Products
- Bioequivalence Assessment
- Challenges In Pharmacovigilance
- Intellectual Property Rights
- Regulatory Approach For Biosimilars
- Globalization Of Biosimilars
- Biosimilars Development In Markets
- Chemical And Analytical Strategies For Biosimilars
- Biological Medicine
- Clinical And Translational Biomarkers
- Cardiovascular Biomarkers
- Molecular Biomarkers
- Biomarkers In Drug Discovery
- Applications In Biomarkers
- Blood Biomarker
- Biomarkers & Research

About Destination London

London is the capital and largest city of England and the United Kingdom, with a population of just under 9 million. It stands on the River Thames in south-east England at the head of a 50-mile (80 km) estuary down to the North Sea, and has been a major settlement for two millennia. The City of London, its ancient core and financial centre, was founded by the Romans as Londinium and retains its medieval boundaries. The City of Westminster, to the west of the City of London, has for centuries hosted the national government and parliament. Since the 19th century, the name "London" has also referred to the metropolis around this core, historically split between the counties of Middlesex, Essex, Surrey, Kent, and Hertfordshire, which since 1965 has largely comprised Greater London, which is governed by 33 local authorities and the Greater London Authority.

As one of the world's major global cities, London exerts a strong influence on its arts, entertainment, fashion, commerce and finance, education, health care, media, science and technology, tourism, and transport and communications. Its GDP (€801.66 billion in 2017) makes it the largest urban economy in Europe, and it is one of the major financial centres in the world. With Europe's largest concentration of higher education institutions, it is home to some of the highest-ranked academic institutions in the world—Imperial College London in natural and applied sciences, the London School of Economics in social sciences, and the comprehensive University College London. London is the most visited city in Europe and has the busiest city airport system in the world. The London Underground is the oldest rapid transit system in the world.





Register Now!

Want to be a Part of the Leading Biosimilars 2023 Event?

Choose your Category:

Academic

Speaker Registration-699 EURO

Delegate Registration-599 EURO

Biosimilars 2023

EuroSciCon

HOW TO REGISTER

Visit: https://biosimilars.euroscicon.com/

Contact Us:

Alexa Rosey | Program Manager
Biosimilars-2023
Email: contact.steve@theannualmeet.com
EuroSciCon Ltd
35 Ruddlesway, Windsor
Berkshire, SL4 5SF

Biosimilars
2023

